
San Francisco Now Hands Out a Buprenorphine Shot the Moment Someone Asks
San Francisco's Maria X Martinez Health Resource Center already offered same-day addiction treatment. What it could not do, until this month, was finish the job in the building. A patient who wanted a long-acting injectable form of buprenorphine had to be sent somewhere else to get it — and at a walk-in clinic where more than three quarters of the 21,000 annual visitors are experiencing homelessness, that detour was where a lot of treatment intentions died.
The city's answer is a $500,000 pilot, launched Nov. 2 and funded almost entirely by the Breaking the Cycle Fund, that lets the SoMa clinic at 555 Stevenson Street store and administer injectable buprenorphine onsite for the first time. The money buys 460 starting doses and 500 follow-up doses across two years, plus secure narcotics safes and auditing software at the pilot sites. The pilot runs through April 2028, and SFDPH plans to extend the model to as many as five additional clinics in 2027 if the workflow holds.
Why an injection changes the moment of entry
Fentanyl broke the old induction script. Because it clears the body unpredictably, a patient who takes buprenorphine tablets too soon after use can be thrown into precipitated withdrawal — a sudden, violent worsening that makes people reluctant to try again. Injectable formulations, started under low-dose protocols, can be given while someone is still using fentanyl, which removes the waiting period that used to function as an exit ramp.
Readiness is also short-lived. The clinic's medical director, Dr. Tanya Majumder, told Mission Local that a patient's willingness to begin treatment can last half an hour. Having the medication in the building converts that half hour into an induction instead of an appointment.
The retention picture is modest but real. A 2025 study led by UCSF's Dr. Sarah Rosenwohl-Mack followed 131 instances of injectable buprenorphine initiation at San Francisco and Oakland safety-net clinics and found 43 percent of patients still on buprenorphine three months later — a number she called encouraging given how many were unstably housed. A 2018 randomized trial of 428 patients had already found weekly and monthly injections at least as effective as daily medication; a 2024 follow-up suggested extended-release formulations may have an edge specifically against fentanyl.
SFDPH says nearly 80 percent of clients who express interest in same- or next-day treatment now get it, and that the number of patients on medication-assisted treatment has risen almost 30 percent over two years.
What the pilot will and will not prove
The evaluation covers overdose events, emergency department use, hospitalizations, retention and engagement — the right outcomes, measured over two years, long enough for the results to land while the model is still cheap to copy.
What it will not prove is scale. Four hundred and sixty starting doses is a rounding error against San Francisco's fentanyl population, and the real constraint on expansion is staffing: a nurse who can administer the injection, a prescriber who can be reached, a safe that satisfies the DEA. The pilot is also philanthropically funded, which means the city is testing a clinical model while deferring who pays for it once the grant ends.
For now the practical change is narrow and specific, which is often how access actually improves. Someone who walks into a clinic on Stevenson Street ready to stop using fentanyl can leave with a month of protection rather than a referral slip and a bus ride. The sites that already offer injectable buprenorphine on demand — Zuckerberg San Francisco General, the SoMa Sobering Center, the Behavioral Health Services Pharmacy and the BEAM program — are worth knowing for anyone weighing opioid addiction treatment before that window opens.
Sources
- San Francisco Department of Public Health, "SFDPH Launches New On Demand Long-acting Injectable Buprenorphine Pilot at Maria X Martinez Health Resource Center"
- Mission Local, "New S.F. pilot program makes fentanyl treatment easier to start. Will patients stick with it?" Nov. 20, 2026
- Rosenwohl-Mack A, et al. Buprenorphine injectable initiation in safety-net clinics, 2025 (PubMed 41442975)
Editorial Board
LADC, LCPC, CASAC
The Rainier Rehab editorial team consists of licensed addiction counselors, healthcare journalists, and recovery advocates dedicated to providing accurate, evidence-based information about substance abuse treatment and rehabilitation.
Related Articles

The Cord Tissue Knew the Dose. It Didn't Know the Withdrawal.
A 94-newborn cohort found umbilical cord methadone tracked maternal dose closely but predicted nothing about withdrawal severity, undercutting dose reduction.

A 25-Study Review Finds Methadone's Heart Risk Doesn't Wait for High Doses
A systematic review published Oct. 15 finds a consistent, dose-related link between methadone and QTc prolongation — and several studies reporting it at low doses.

Doctors Know the Rules for Treating Teens With Opioids. They Can't Tell What the Rules Allow.
A survey of 600 US pediatric prescribers finds legal ambiguity, not ignorance, is what predicts whether a clinician ever offers buprenorphine to an adolescent with opioid use disorder.